FDA approves Gilead drug for metastatic breast cancer
2023-02-06
临床研究抗体药物偶联物
Gilead Sciences announced this week that the U.S. FDA has approved its breast cancer drug for the treatment of adults with HR+/HER2- metastatic breast cancer.
Sold as Trodelvy, the drug is a first-in-class Trop-2-directed antibody-drug conjugate. Trop-2 s a cell surface antigen that can be found in more than 90% of breast and bladder cancers, and Gilead designed Trodelvy to include a proprietary linker that enhances delivery potency to cancer cells.
The drug is already approved in more than 40 countries, with multiple additional regulatory reviews underway worldwide, for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer.
The recent indication was supported by results from the phase 3 trial TROPiCS-02. The global, multicenter, open-label, study included 543 patients with HR+/HER2- metastatic breast cancer who had been previously treated with endocrine therapy, CDK4/6 inhibitors, and two to four lines of chemotherapy for metastatic disease. All primary and secondary endpoints were met, not only did Trodelvy improved progression-free survival for patients in comparison to chemotherapy but it also demonstrated a positive overall safety and tolerability profile.
Gilead picked up the drug back in 2020, with its $21 billion Immunomedics buy.
Since the approval last Friday, Gilead's shares surged by nearly 3%.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
-适应症
-靶点
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。